Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
OLSALAZINE SODIUM
Atnahs Pharma UK Limited
A07EC; A07EC03
OLSALAZINE SODIUM
250 milligram(s)
Capsule
Product subject to prescription which may be renewed (B)
Aminosalicylic acid and similar agents; olsalazine
Marketed
2014-09-26
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dipentum 250mg hard Capsules. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250mg olsalazine sodium. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Beige, opaque, hard gelatin size 1 capsule radially printed "DIPENTUM 250 mg" in black. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of mild to moderate acute ulcerative colitis with or without corticosteroids. The drug may also be used in the long term maintenance or remission of ulcerative colitis. It is particularly useful where patients cannot tolerate sulphazalazine because of sulpha intolerance. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION To be taken in divided doses with meals GENERAL Olsalazine taken on an empty stomach may sometimes lead to loose stools or diarrhoea. By taking the drug at the end of a meal, this may be avoided. Acute Mild Disease _Adults including the elderly:_ Commence on 1 g daily in divided doses taken at the end of meals. Depending on the patient’s response, the dose may be titrated upwards over a period of one week to a maximum of 3g daily. Concommitant oral or rectal steroids may be used. In the event of drug related diarrhoea occurring, it may be transient. If it is not, dose may be reduced; where diarrhoea continues despite this reduction the drug should be stopped. A single dose should not exceed 1 g. LONG TERM MAINTENANCE OF REMISSION _Adults including the elderly:_ Two capsules may be taken twice daily with food. _Children and infants_: No specific recommendations are made. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Preberite celoten dokument